RFA-CA-25-033
Glioblastoma Therapeutics Network (GTN; U19 Clinical Trial Required)
Summary
Glioblastoma Therapeutics Network: Translational Drug Development
The National Cancer Institute seeks applications to accelerate therapeutic development for adult glioblastoma, a disease where effective agents capable of crossing the blood-brain barrier remain limited. This program funds research spanning late preclinical work through investigational new drug (IND) studies and early Phase 0/1 clinical trials in humans—a translational pathway that bridges the gap between laboratory discovery and initial human testing. Applicants may develop novel therapeutic agents or pursue drug repurposing strategies, where existing agents approved for other indications are evaluated for GBM efficacy following appropriate preclinical validation. The intended outcome is a pipeline of promising candidates ready for seamless transition to later-stage NCI-supported clinical trials.
Critical structural requirement: Applicants must establish a highly collaborative GBM Therapeutics Network (GTN) with cross-cutting teams; this consortium model is mandatory, not optional. Each team must be capable of advancing therapeutic agent(s) from preclinical development through IND-enabling studies into pilot human studies.
- Who can apply: Institutions with capacity to form a collaborative GTN spanning preclinical, IND, and early clinical research; projects focused solely on preclinical or clinical work alone are out of scope.
- Funding & project length: Not stated.
- Award mechanism: UH3 (cooperative agreement).
- Key dates: Not stated.
- Best fit for: Oncology and translational research teams in drug development, neuro-oncology, and clinical pharmacology with expertise in blood-brain barrier penetration and Phase 0/1 trial design.
Insights (6)
Mandatory GTN consortium structure requires deep cross-functional team integration
This NOFO mandates establishment of a GBM Therapeutics Network with cross-cutting teams—this is not optional infrastructure but a core structural requirement. Success depends on assembling and demonstrating seamless collaboration between preclinical, translational, regulatory, and clinical teams capable of moving agents from late preclinical through Phase 0/1 trials as a unified unit.
Translational pipeline maturity and BBB penetration expertise are competitive differentiators
Applicants with demonstrated capability in blood-brain-barrier drug design, formulation optimization, and translational pathway experience will be significantly advantaged. Preliminary data showing BBB penetration, pharmacokinetic/pharmacodynamic profiles, and clear IND-readiness will strengthen competitiveness over purely preclinical or purely clinical proposals.
Scope requirement spans pre-clinical through Phase 0/1—single-stage projects are out of scope
The NOFO explicitly requires projects to span late preclinical development through early clinical studies in humans. Applicants proposing only preclinical work or only clinical validation will not meet the mandatory scope. This effectively requires dual expertise and infrastructure (animal models, GMP manufacturing, IND regulatory pathway, and human trial capacity) within a single application.
Clinical trial leadership experience essential; early-stage investigators may face structural barriers
The requirement for Phase 0/1 clinical trial execution as a core deliverable favors applicants with established clinical trial infrastructure and regulatory experience. Early-stage investigators without prior IND or clinical trial leadership may struggle unless partnered with experienced clinical co-investigators, making this less accessible for ESI-only teams.
Drug repurposing pathway offers faster translational timeline and reduced preclinical burden
The NOFO explicitly welcomes repurposed agents (approved for other indications) following appropriate preclinical validation. This pathway may accelerate IND preparation and clinical entry compared to novel agents, and could be strategically advantageous for teams with access to existing pharmacology and safety data.
UH3 mechanism and network structure suggest moderate award number with high bar for integration
The UH3 mechanism combined with mandatory GTN consortium structure indicates this is likely a limited number of large, integrated awards rather than many small grants. Competition will favor applications demonstrating proven cross-functional team dynamics and clear operational integration plans, not just co-investigator lists.
Key Facts
Deadline
—
Posted
Wed, September 17, 2025
Keywords
Research Areas
Gotchas (3)
This NOFO requires establishment of a highly collaborative GBM Therapeutics Network (GTN) with cross-cutting teams—this is a mandatory structural/consortium requirement, not optional
95%
Source Text
“To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through IND studies, into pilot clinical studies in humans.”
Projects must span from late pre-clinical through early Phase 0/1 clinical studies—this is a required scope that differs from typical single-stage grants and may disqualify projects focused only on pr
92%
Source Text
“The scope of the NOFO, from late pre-clinical through early (Phase 0/1) clinical studies, uniquely spans a gap in the GBM drug development process.”
Clinical trial component is required as part of the project scope (Phase 0/1 studies in humans)—applicants proposing only preclinical work may be out of scope
93%
Source Text
“each team capable of driving therapeutic agent(s) from pre-clinical development, through IND studies, into pilot clinical studies in humans”